DexCom, Inc. (DXCM)
Healthcare · Medical - Devices · Data as of 2026-10-22
Bottom line
DXCM is trading near its usual valuation, in the middle of its recent price range, and recent volume suggests money flowing out. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Cheap-looking, with quality flags (Yellow)
DXCM trades at 30× earnings, below its own 5-year average of 78× and roughly in line with similar healthcare companies we track (28×, 53 peers). Historically this has been on the cheaper side for the stock. Its free-cash-flow yield is about 4.8%. Growth is slower than its 3-year pace, which deserves some caution. Its current multiple sits around the 5th percentile of its own last five years — toward the low end of its own range.
Quality check: revenue growth has slowed to about 16% a year (3-year pace about 17%; analysts expect about 11% next year), while the multiple sits at the low end of its own history. That combination can mean the market is pricing a slower business rather than offering a bargain.
Price zones — In the middle of its recent range (Yellow)
At $78.32, the stock sits between its recent support and resistance levels. Over the past year DXCM has traded between $54.11 and $92.59; its historical support zone sits near $74.27 and resistance near $87.10. It is above one of its moving averages and below the other — a mixed trend picture.
52-week range $54.11–$92.59 · 50-day average $87.10 · 200-day average $74.27
Money flow — Money is flowing out (Red)
Recent trading in DXCM shows more volume on falling days than rising days, a pattern often described as distribution. Volume on up days has been about 0.9× volume on down days over the last 30 sessions.
Dividends & company facts
DXCM doesn't pay a dividend, but it bought back $472 million of its shares in fiscal 2025, about 1.6% of its market value. Its share count fell 4.0% over the past year and 8.3% over five.
- Buybacks
- 1.6% (fiscal 2025)
- Shares, past year
- -4.0%
- Revenue, 12 months
- $5.0B
- Profit, 12 months
- $1000M
- Employees
- 11,050
- CEO
- Jacob Steven Leach
- Headquarters
- San Diego, CA
- Listed since
- 2005 · NASDAQ
About the company
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners.
Related stocks
一句话结论
DXCM 估值接近其惯常水平，处于近期价格区间的中部，近期成交量显示资金正在流出。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 看似便宜，但有质量警示
DXCM 目前的市盈率为 30×，低于其自身 5 年平均的 78×，并且大致持平于我们追踪的同类Healthcare公司（28×，53 家）。从历史来看，这属于该股较便宜的一侧。其自由现金流收益率约为 4.8%。增速已慢于其 3 年的平均步伐，这一点值得留意。它当前的估值倍数大约位于自身过去五年分布的第 5 百分位——处于自身区间的偏低位置。
质量核对：营收增速已放缓至每年约 16%（3 年平均步伐约为 17%；分析师预期明年约为 11%），而估值倍数正处于自身历史的低位。这样的组合可能意味着市场在为一个增长更慢的业务定价，而不是在给出便宜的价格。
价格区间 — 处于近期区间的中部
目前价格为 $78.32，位于其近期的支撑位与阻力位之间。过去一年 DXCM 的价格在 $54.11 到 $92.59 之间波动；其历史支撑区在 $74.27 附近，阻力区在 $87.10 附近。它位于其中一条均线上方、另一条下方——趋势信号并不一致。
资金流向 — 资金正在流出
DXCM 近期下跌日的成交量高于上涨日，这种形态常被称为派发。过去 30 个交易日，上涨日的成交量约为下跌日的 0.9×。
股息与公司概况
DXCM 不派发股息，但在 2025 财年回购了 4.7亿美元 的股票，约占市值的 1.6%。其股数过去一年减少了 4.0%，五年减少了 8.3%。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.